In patients with acute ischemic stroke after exclusion of cerebral amyloid angiopathy, argatroban improves early neurological function but does not improve functional outcome at 90 days, with severe white matter hyperintensities identified as a potential effect modifier.
Argatroban significantly reduced early neurological deterioration in acute ischemic stroke patients with non-amyloid CSVD.
No significant difference in favorable functional outcome at 90 days was observed between the argatroban and control groups.
Severe white matter hyperintensities acted as a potential effect modifier of argatroban's efficacy.
Argatroban treatment was associated with a favorable safety profile, with no intracranial hemorrhages occurring in the argatroban group.
The study design was a retrospective cohort study using interaction terms to test for effect modification by non-amyloid CSVD imaging markers.
This research examined whether visible signs of small vessel disease in the brain (non-amyloid type) affect how well a blood-thinning drug called argatroban works in patients who have had an acute ischemic stroke (a stroke caused by a blood clot). The researchers looked at 139 stroke patients treated at a Chinese hospital between 2022 and 2023, comparing those who received argatroban to those who did not. Patients with a condition called cerebral amyloid angiopathy — a separate cause of small vessel disease associated with higher bleeding risk — were excluded from the study. The study found that argatroban was effective at preventing early worsening of neurological symptoms, with patients in the argatroban group being much less likely to experience early neurological deterioration. However, there was no meaningful difference between the two groups in terms of functional recovery three months after the stroke, with about 80% of patients in both groups achieving a good functional outcome. Importantly, argatroban appeared to work better in patients who did not have severe white matter hyperintensities — a type of brain imaging finding that reflects damage to the brain's white matter from small vessel disease. Only one bleeding complication occurred across the entire study, and it was in the control group, suggesting argatroban was safe in this population. This research suggests that imaging features visible on brain scans — particularly severe white matter changes — may help doctors predict which stroke patients are most likely to benefit from argatroban treatment. The finding that severe white matter hyperintensities may reduce argatroban's effectiveness is a new hypothesis that the authors note requires confirmation in larger, prospective studies before it can inform clinical practice.
Liu F, Wu Q, Lin Y, Chen J. (2026). Impact of non-amyloid cerebral small vessel disease on the efficacy and safety of argatroban in acute ischemic stroke: a retrospective cohort study.. Frontiers in neurology. https://doi.org/10.3389/fneur.2026.1861639